Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 CHF | +4.94% | +8.97% | +143.55% |
24/04 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
17/04 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.71M 1.64B | Sales 2023 | 33.56M 36.78M 3.06B | Capitalization | 128M 141M 11.69B |
---|---|---|---|---|---|
Net income 2022 | -14M -15.34M -1.28B | Net income 2023 | -13M -14.24M -1.19B | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.2M 2.01B | Net cash position 2023 | 12M 13.15M 1.09B | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.77% |
1 day | +4.94% | ||
1 week | +8.97% | ||
Current month | +31.17% | ||
1 month | +23.91% | ||
3 months | +63.46% | ||
6 months | +129.73% | ||
Current year | +143.55% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17/23/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 14/18/14 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Date | Price | Change | Volume |
---|---|---|---|
28/24/28 | 8.5 | +4.94% | 447,957 |
27/24/27 | 8.1 | +1.25% | 79,384 |
24/24/24 | 8 | +0.13% | 66,523 |
23/24/23 | 7.99 | +0.50% | 118,615 |
22/24/22 | 7.95 | +1.92% | 86,555 |
Delayed Quote Swiss Exchange, May 28, 2024 at 09:01 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
+143.55% | 327M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- KURN Stock